Maurizio Raiteri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maurizio Raiteri has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Giambattista Bonanno
Department of Pharmacy (DiFAR), University of Genoa, Viale Cembrano 4, I-16148 Genova, Italy
4 shared publications Giovanni Fontana
Dipartimento di Medicina Sperimentale, Sezione di Farmacologia e Tossicologia, Viale Cembrano 4, 16148 Genova, Italy
3 shared publications- Anna Fassio
Department of Experimental Medicine, Università degli Studi di Genova, Viale Benedetto XV 3, 16132 Genova, Italy
2 shared publications Claudio Munari
Clinica Neurochirurgica, Università di Genova, Ospedale S. Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy
2 shared publications- Ernesto Fedele
Pharmacology and Toxicology Unit, Department of Pharmacy, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Cembrano 4, 16148 Genoa, Italy
2 shared publications Giovanna Schmid
Department of Experimental Medicine, Pharmacology and Toxicology Section, Viale Cembrano 4, Genoa, Italy
2 shared publications
Latest Publications
- Open Access
- 18 July 2018
- Published by JSTOR
- p. 193-214
Microdialysis study in vivo of the nitric oxide/cGMP pathway in the hippocampus and cerebellum of adult and aged rats
- 18 July 2018
- Published by JSTOR
- p. 193-214
Open AccessMicrodialysis study in vivo of the nitric oxide/cGMP pathway in the hippocampus and cerebellum of adult and aged rats
- 1 November 1999
- Published by Elsevier in Neuropharmacology
- Vol. 38 (11) , 1789-1795
Selective block of rat and human neocortex GABAB receptors regulating somatostatin release by a GABAB antagonist endowed with cognition enhancing activity
- 1 November 1999
- Published by Elsevier in Neuropharmacology
- Vol. 38 (11) , 1789-1795
Selective block of rat and human neocortex GABAB receptors regulating somatostatin release by a GABAB antagonist endowed with cognition enhancing activity
- 27 July 1999
- Published by Elsevier in Neuropharmacology
- Vol. 38 (9) , 1273-1279
Enhanced benzodiazepine and ethanol actions on cerebellar GABAA receptors mediating glutamate release in an alcohol-sensitive rat line
- 27 July 1999
- Published by Elsevier in Neuropharmacology
- Vol. 38 (9) , 1273-1279
Enhanced benzodiazepine and ethanol actions on cerebellar GABAA receptors mediating glutamate release in an alcohol-sensitive rat line
- 19 July 1999
- Published by Wiley in Journal of Neuroscience Research
- Vol. 57 (3) , 324-331
GABA induces norepinephrine exocytosis from hippocampal noradrenergic axon terminals by a dual mechanism involving different voltage‐sensitive calcium channels
- 19 July 1999
- Published by Wiley in Journal of Neuroscience Research
- Vol. 57 (3) , 324-331
GABA induces norepinephrine exocytosis from hippocampal noradrenergic axon terminals by a dual mechanism involving different voltage‐sensitive calcium channels
- 1 July 1999
- Published by Wiley in European Journal of Neuroscience
- Vol. 11 (7) , 2351-2358
Native human neocortex release‐regulating dopamine D2 type autoreceptors are dopamine D2 subtype
Dopamine (DA) autoreceptors expressed at DA nerve terminals regulate DA release. Considerable evidence has indicated that, in rodents, these autoreceptors belong to the D2 type of the DA receptor family, which, in turn, comprises the D2, D3 and D4 subtypes. We investigated here, for the first time, the subclassification of native human DA autoreceptors by studying the release of [3H]DA evoked by electrical stimulation in fresh human neocortical slices. The results have been compared with those obtained in three animal systems: rat neocortical and striatal slices and rat mesencephalic neuronal cultures. In human neocortical slices, the D2/D3 receptor agonist quinpirole (1 n m–10 μm) inhibited tritium release with a calculated EC50 of 17 n m and a maximal inhibition of ≈ 75% reached at 1 μm. In the presence of the D2/D3 receptor antagonist (–)‐sulpiride (0.1 and 1 μm), the concentration–response curve of quinpirole was shifted to the right, and the apparent pA2 mean value was 8.5 (8.14–8.77); on the other hand, the inhibitory effects of quinpirole were not affected by the D3 receptor‐selective antagonist [7‐N,N‐dipropylamino‐5,6,7,8‐tetrahydro‐naphtho(2,3b) dihydro,2,3‐furane] (S 14297) and the D4 receptor‐selective antagonist 3‐(4‐[4‐chlorophenyl]piperazin‐1‐yl)‐methyl‐1H‐pyrrolo [2,3‐b]pyridine (L‐745,870) (0.01–1 μm in each case). Superimposable results have been obtained when the release was elicited from rat striatal slices or dopamine mesencephalic neurons in culture, whereas quantitative differences emerged in the case of rat cortical slices. It is concluded that in human brain, as well as in rat brain, the release of DA in the terminal region of midbrain dopaminergic neurons is regulated through autoreceptors of the D2 subtype.
- 1 July 1999
- Published by Wiley in European Journal of Neuroscience
- Vol. 11 (7) , 2351-2358
Native human neocortex release‐regulating dopamine D2 type autoreceptors are dopamine D2 subtype
Dopamine (DA) autoreceptors expressed at DA nerve terminals regulate DA release. Considerable evidence has indicated that, in rodents, these autoreceptors belong to the D2 type of the DA receptor family, which, in turn, comprises the D2, D3 and D4 subtypes. We investigated here, for the first time, the subclassification of native human DA autoreceptors by studying the release of [3H]DA evoked by electrical stimulation in fresh human neocortical slices. The results have been compared with those obtained in three animal systems: rat neocortical and striatal slices and rat mesencephalic neuronal cultures. In human neocortical slices, the D2/D3 receptor agonist quinpirole (1 n m–10 μm) inhibited tritium release with a calculated EC50 of 17 n m and a maximal inhibition of ≈ 75% reached at 1 μm. In the presence of the D2/D3 receptor antagonist (–)‐sulpiride (0.1 and 1 μm), the concentration–response curve of quinpirole was shifted to the right, and the apparent pA2 mean value was 8.5 (8.14–8.77); on the other hand, the inhibitory effects of quinpirole were not affected by the D3 receptor‐selective antagonist [7‐N,N‐dipropylamino‐5,6,7,8‐tetrahydro‐naphtho(2,3b) dihydro,2,3‐furane] (S 14297) and the D4 receptor‐selective antagonist 3‐(4‐[4‐chlorophenyl]piperazin‐1‐yl)‐methyl‐1H‐pyrrolo [2,3‐b]pyridine (L‐745,870) (0.01–1 μm in each case). Superimposable results have been obtained when the release was elicited from rat striatal slices or dopamine mesencephalic neurons in culture, whereas quantitative differences emerged in the case of rat cortical slices. It is concluded that in human brain, as well as in rat brain, the release of DA in the terminal region of midbrain dopaminergic neurons is regulated through autoreceptors of the D2 subtype.
- 4 December 1998
- Published by Elsevier in European Journal of Pharmacology
- Vol. 362 (2-3) , 143-148
GABAB receptors as potential targets for drugs able to prevent excessive excitatory amino acid transmission in the spinal cord
- 4 December 1998
- Published by Elsevier in European Journal of Pharmacology
- Vol. 362 (2-3) , 143-148
GABAB receptors as potential targets for drugs able to prevent excessive excitatory amino acid transmission in the spinal cord
- 15 September 1997
- Published by Wiley in Journal of Neuroscience Research
- Vol. 49 (6) , 732-738
Gp120 can revert antagonism at the glycine site of NMDA receptors mediating GABA release from cultured hippocampal neurons
The effects of the human immunodeficiency virus type 1 envelope protein gp120 on the release of GABA elicited by N-methyl-D-aspartate (NMDA) from rat hippocampal neurons in primary culture has been investigated. NMDA (1–300 μM) increased in a concentration-dependent manner (EC50 = 37.9 ± 12 μM) the release of [3H]-GABA. The effect of 100 μM NMDA was prevented by 30 μM of the GABA transport inhibitor N-(4,4-diphenyl-3-butenyl)guvacine (SKF 100330A). Glycine (10 μM) or gp120 (0.01 μM) affected neither the basal nor the NMDA-evoked [3H]-GABA release. The NMDA (100 μM)-evoked release was prevented by 5,7-dichloro-kynurenic acid (5,7-DCKA), a selective antagonist at the glycine site of the NMDA receptor, in a concentration-dependent manner (IC50 ≃ 0.3 μM). Glycine (3–10 μM) or gp120 (0.003–0.01 μM) produced reversal of the 5,7-DCKA antagonism in a way that suggested competition at a same site; gp120 was at least 3 orders of magnitude more potent than glycine. It is suggested that gp120 may mimic glycine at NMDA receptors. J. Neurosci. Res. 49:732–738, 1997.
- 15 September 1997
- Published by Wiley in Journal of Neuroscience Research
- Vol. 49 (6) , 732-738
Gp120 can revert antagonism at the glycine site of NMDA receptors mediating GABA release from cultured hippocampal neurons
The effects of the human immunodeficiency virus type 1 envelope protein gp120 on the release of GABA elicited by N-methyl-D-aspartate (NMDA) from rat hippocampal neurons in primary culture has been investigated. NMDA (1–300 μM) increased in a concentration-dependent manner (EC50 = 37.9 ± 12 μM) the release of [3H]-GABA. The effect of 100 μM NMDA was prevented by 30 μM of the GABA transport inhibitor N-(4,4-diphenyl-3-butenyl)guvacine (SKF 100330A). Glycine (10 μM) or gp120 (0.01 μM) affected neither the basal nor the NMDA-evoked [3H]-GABA release. The NMDA (100 μM)-evoked release was prevented by 5,7-dichloro-kynurenic acid (5,7-DCKA), a selective antagonist at the glycine site of the NMDA receptor, in a concentration-dependent manner (IC50 ≃ 0.3 μM). Glycine (3–10 μM) or gp120 (0.003–0.01 μM) produced reversal of the 5,7-DCKA antagonism in a way that suggested competition at a same site; gp120 was at least 3 orders of magnitude more potent than glycine. It is suggested that gp120 may mimic glycine at NMDA receptors. J. Neurosci. Res. 49:732–738, 1997.
- 23 November 1996
- Published by Wiley in Journal of Neurochemistry
- Vol. 67 (5) , 1974-1981
Nicotinic Autoreceptors Mediating Enhancement of Acetylcholine Release Become Operative in Conditions of “Impaired” Cholinergic Presynaptic Function
The existence in the mammalian CNS of release-inhibiting muscarinic autoreceptors is well established. In contrast, few reports have focused on nicotinic autoreceptors mediating enhancement of acetylcholine (ACh) release. Moreover, it is unclear under what conditions the function of one type of autoreceptor prevails over that of the other. Rat cerebrocortex slices, prelabeled with [3H]choline, were stimulated electrically at 3 or 0.1 Hz. The release of [3H]ACh evoked at both frequencies was inhibited by oxotremorine, a muscarinic receptor agonist, and stimulated by atropine, a muscarinic antagonist. Nicotine, ineffective at 3 Hz, enhanced [3H]ACh release at 0.1 Hz; mecamylamine, a nicotinic antagonist, had no effect at 3 Hz but inhibited [3H]ACh release at 0.1 Hz. The cholinesterase inhibitor neostigmine decreased [3H]ACh release at 3 Hz but not at 0.1 Hz; in the presence of atropine, neostigmine potentiated [3H]ACh release, an effect blocked by mecamylamine. In synaptosomes depolarized with 15 mM KCI, ACh inhibited [3H]ACh release; this inhibition was reversed to an enhancement when the external [Ca2+] was lowered. The same occurred when, at 1.2 mM Ca2+, external [K+] was decreased. Oxotremorine still inhibited [3H]ACh release at 0.1 mM Ca2+. When muscarinic receptors were inactivated with atropine, the K+ (15 mM)-evoked release of [3H]ACh (at 0.1 mM Ca2+) was potently enhanced by ACh acting at nicotinic receptors (EC50⋍ 0.6 µM). In conclusion, synaptic ACh concentration does not seem to determine whether muscarinic or nicotinic autoreceptors are activated. Although muscarinic autoreceptors prevail under normal conditions, nicotinic autoreceptors appear to become responsive to endogenous ACh and to exogenous nicotinic agents under conditions mimicking impairment of ACh release. Our data may explain in part the reported efficacy of cholinesterase inhibitors (and nicotinic agonists) in Alzheimer's disease.
- 23 November 1996
- Published by Wiley in Journal of Neurochemistry
- Vol. 67 (5) , 1974-1981
Nicotinic Autoreceptors Mediating Enhancement of Acetylcholine Release Become Operative in Conditions of “Impaired” Cholinergic Presynaptic Function
The existence in the mammalian CNS of release-inhibiting muscarinic autoreceptors is well established. In contrast, few reports have focused on nicotinic autoreceptors mediating enhancement of acetylcholine (ACh) release. Moreover, it is unclear under what conditions the function of one type of autoreceptor prevails over that of the other. Rat cerebrocortex slices, prelabeled with [3H]choline, were stimulated electrically at 3 or 0.1 Hz. The release of [3H]ACh evoked at both frequencies was inhibited by oxotremorine, a muscarinic receptor agonist, and stimulated by atropine, a muscarinic antagonist. Nicotine, ineffective at 3 Hz, enhanced [3H]ACh release at 0.1 Hz; mecamylamine, a nicotinic antagonist, had no effect at 3 Hz but inhibited [3H]ACh release at 0.1 Hz. The cholinesterase inhibitor neostigmine decreased [3H]ACh release at 3 Hz but not at 0.1 Hz; in the presence of atropine, neostigmine potentiated [3H]ACh release, an effect blocked by mecamylamine. In synaptosomes depolarized with 15 mM KCI, ACh inhibited [3H]ACh release; this inhibition was reversed to an enhancement when the external [Ca2+] was lowered. The same occurred when, at 1.2 mM Ca2+, external [K+] was decreased. Oxotremorine still inhibited [3H]ACh release at 0.1 mM Ca2+. When muscarinic receptors were inactivated with atropine, the K+ (15 mM)-evoked release of [3H]ACh (at 0.1 mM Ca2+) was potently enhanced by ACh acting at nicotinic receptors (EC50⋍ 0.6 µM). In conclusion, synaptic ACh concentration does not seem to determine whether muscarinic or nicotinic autoreceptors are activated. Although muscarinic autoreceptors prevail under normal conditions, nicotinic autoreceptors appear to become responsive to endogenous ACh and to exogenous nicotinic agents under conditions mimicking impairment of ACh release. Our data may explain in part the reported efficacy of cholinesterase inhibitors (and nicotinic agonists) in Alzheimer's disease.
- 1 January 1996
- Published by Wiley in Journal of Neurochemistry
- Vol. 66 (1) , 161-168
Characterization of the Glutamate Receptors Mediating Release of Somatostatin from Cultured Hippocampal Neurons
L‐Glutamate, NMDA, dl‐α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionate (AMPA), and kainate (KA) increased the release of somatostatin‐like immunoreactivity (SRIF‐LI) from primary cultures of rat hippocampal neurons. In Mg2+‐containing medium, the maximal effects (reached at ∼100 µM) amounted to 737% (KA), 722% (glutamate), 488% (NMDA), and 374% (AMPA); the apparent affinities were 22 µM (AMPA), 39 µM (glutamate), 41 µM (KA), and 70 µM (NMDA). The metabotropic receptor agonist trans‐1‐aminocyclopentane‐1,3‐dicarboxylate did not affect SRIF‐LI release. The release evoked by glutamate (100 µM) was abolished by 10 µM dizocilpine (MK‐801) plus 30 µM 1‐aminophenyl‐4‐methyl‐7,8‐methylenedioxy‐5H‐2,3‐benzodiazepine (GYKI 52466). Moreover, the maximal effect of glutamate was mimicked by a mixture of NMDA + AMPA. The release elicited by NMDA was sensitive to MK‐801 but insensitive to GYKI 52466. The AMPA‐ and KA‐evoked releases were blocked by 6,7‐dinitroquinoxaline‐2,3‐dione (DNQX) or by GYKI 52466 but were insensitive to MK‐801. The release of SRIF‐LI elicited by all four agonists was Ca2+ dependent, whereas only the NMDA‐evoked release was prevented by tetrodotoxin. Removal of Mg2+ caused increase of basal SRIF‐LI release, an effect abolished by MK‐801. Thus, glutamate can stimulate somatostatin release through ionotropic NMDA and AMPA/KA receptors. Receptors of the KA type (AMPA insensitive) or metabotropic receptors appear not to be involved.
- 1 January 1996
- Published by Wiley in Journal of Neurochemistry
- Vol. 66 (1) , 161-168
Characterization of the Glutamate Receptors Mediating Release of Somatostatin from Cultured Hippocampal Neurons
L‐Glutamate, NMDA, dl‐α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionate (AMPA), and kainate (KA) increased the release of somatostatin‐like immunoreactivity (SRIF‐LI) from primary cultures of rat hippocampal neurons. In Mg2+‐containing medium, the maximal effects (reached at ∼100 µM) amounted to 737% (KA), 722% (glutamate), 488% (NMDA), and 374% (AMPA); the apparent affinities were 22 µM (AMPA), 39 µM (glutamate), 41 µM (KA), and 70 µM (NMDA). The metabotropic receptor agonist trans‐1‐aminocyclopentane‐1,3‐dicarboxylate did not affect SRIF‐LI release. The release evoked by glutamate (100 µM) was abolished by 10 µM dizocilpine (MK‐801) plus 30 µM 1‐aminophenyl‐4‐methyl‐7,8‐methylenedioxy‐5H‐2,3‐benzodiazepine (GYKI 52466). Moreover, the maximal effect of glutamate was mimicked by a mixture of NMDA + AMPA. The release elicited by NMDA was sensitive to MK‐801 but insensitive to GYKI 52466. The AMPA‐ and KA‐evoked releases were blocked by 6,7‐dinitroquinoxaline‐2,3‐dione (DNQX) or by GYKI 52466 but were insensitive to MK‐801. The release of SRIF‐LI elicited by all four agonists was Ca2+ dependent, whereas only the NMDA‐evoked release was prevented by tetrodotoxin. Removal of Mg2+ caused increase of basal SRIF‐LI release, an effect abolished by MK‐801. Thus, glutamate can stimulate somatostatin release through ionotropic NMDA and AMPA/KA receptors. Receptors of the KA type (AMPA insensitive) or metabotropic receptors appear not to be involved.